This article is more than 5 years old. Information may no longer be current.
Arrhythmia Disorders section will focus on therapeutics, devices, new data
Click Here to Manage Email Alerts
As Section Editor of the former Electrophysiology and Arrhythmia Disorders section of the Cardiology Today Editorial Board practically since its inception, I’ve been a part of the publication’s evolution in an effort to stay in touch with what matters most to us as physicians in clinical cardiology practice.
The changes that commence with this month’s issue are meant to do just that; while you can expect the same news and clinical trial information from Cardiology Today in the field of electrophysiology and arrhythmia disorders, the articles will be shorter, more concise and focused, to provide you with expert thought on how the news applies to your practice.
In the Arrhythmia Disorders section, we’ll cover articles of clinical interest spanning the entire range of electrophysiology, from new genetic observations on inherited arrhythmia syndromes to the latest therapeutic approaches, including drugs, devices and ablation. We’re going to continue to bring you clinical trial news from meetings such as the Heart Rhythm Society’s Scientific Sessions. You’ll hear from me as well as other members of the board in commentaries throughout the year.
Finally, the very knowledgeable experts that join me on the Arrhythmia Disorders section of the revamped Cardiology Today Editorial Board and I will take an active role in providing you perspectives on the trial results and important news in the field. We’ll address the question of whether the new device or drug trial results should change your practice and how. We welcome your comments and suggestions at Editor@CardiologyToday.com.
Douglas Zipes, MD, is distinguished professor at the Indiana University School of Medicine Krannert Institute of Cardiology.